Legg Mason Asset Management’s Myriad Genetics MYGN Stock Holding History

Legg Mason Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-15,200	Closed	-$587K	–	138
2014 Q3	$587K	Sell	15,200 -1,800	-11%	-$67.2K	0.41%	100
2014 Q2	$662K	Sell	17,000 -1,500	-8%	-$55.8K	0.42%	107
2014 Q1	$633K	Sell	18,500 -2,200	-11%	-$68.2K	0.37%	119
2013 Q4	$435K	Sell	20,700 -3,900	-16%	-$98.6K	0.25%	122
2013 Q3	$579K	Sell	24,600 -2,200	-8%	-$62.5K	0.31%	120
2013 Q2	$721K	Buy	+26,800	New	+$777K	0.39%	103

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BTS

BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Legg Mason Asset Management's MYGN Position: Q4 2014 in Review

Legg Mason Asset Management sold out of Myriad Genetics (MYGN) in Q4 2014, closing a stake of 15,200 shares — an estimated $587K sold.

Legg Mason Asset Management first reported a position in MYGN in Q2 2013 and held it in 6 quarters. The position peaked at $721K in Q2 2013. 272 funds tracked by Wall St. Rank hold MYGN as of Q4 2014.

Legg Mason Asset Management reported no remaining Myriad Genetics position as of Q4 2014 after selling out during the quarter.
Legg Mason Asset Management sold 15,200 Myriad Genetics shares in Q4 2014, an estimated $587K.
Legg Mason Asset Management first reported a position in Myriad Genetics in Q2 2013 and held it in 6 quarters.
Legg Mason Asset Management's Myriad Genetics position peaked at $721K in Q2 2013.
272 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2014.

Based on Legg Mason Asset Management's 13F filing for Q4 2014, filed 17 Feb 2015.